Main Article

Genoptix’s growth has not stopped since the testing provider announced its initial public offering (IPO) in October 2007 at a price of $17 a share, and saw that price jump to $25.35 per share on October 30, its first day of trading on the Nasdaq. The growth has continued in both revenue and volume—recently released Q108 results showed a 78 percent growth in volume and 109 percent growth in revenue compared to Q107.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

July 2008 - Table of Contents

LIR July 2008 (full PDF issue)

Survey Finds Outreach Labs Growing at 4 Times the Rate of National Labs

Valuations Close to All-Time High; Labs Continue to Attract Private Equity Interest

Former Quest Execs Acquire New Jersey-Based Genatom and Launch Manhattan Lab

Breaking Legislative Update: House Passes Medicare Bill Repeal Competitive Bidding, Physician Fee Fix

Spectrum Labs Implements Phlebotomist Payment Collection Program

Have Rock Solid Business Infrastructure, Will Grow Pathology Business

CDC Report Assesses Lab Market, Calls for Medicare Changes

Rosetta Genomics Buys Parkway Clinical Labs for $3 Million+

Post IPO, Genoptix’s Focus Is on Growing Volume and Expanding Sales Operations

Lab Stocks Inch Upward in June, but Down 4% So Far in 2008

Sonic Healthcare to Acquire Two German Labs for Over $130 Million